TD Cowen Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price

GoodRx (NASDAQ:GDRX) had its price objective dropped by TD Cowen from $7.00 to $6.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. TD Cowen’s target price indicates a potential upside of 99.00% from the company’s previous close.

Other equities analysts have also issued reports about the company. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $6.00 price target on shares of GoodRx in a research note on Monday, August 11th. UBS Group cut their target price on GoodRx from $4.25 to $4.00 and set a “neutral” rating for the company in a research note on Thursday. Weiss Ratings downgraded shares of GoodRx from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Mizuho lowered their price target on shares of GoodRx from $5.00 to $4.00 and set a “neutral” rating on the stock in a report on Thursday. Finally, Raymond James Financial downgraded shares of GoodRx from a “strong-buy” rating to an “outperform” rating in a report on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $5.61.

GoodRx Stock Performance

GDRX stock traded down $0.10 on Monday, reaching $3.02. 936,275 shares of the company were exchanged, compared to its average volume of 2,512,706. GoodRx has a 12 month low of $2.95 and a 12 month high of $5.81. The stock’s fifty day moving average price is $4.02 and its 200 day moving average price is $4.28. The firm has a market capitalization of $1.05 billion, a PE ratio of 33.50, a PEG ratio of 1.62 and a beta of 1.19. The company has a debt-to-equity ratio of 0.81, a current ratio of 3.11 and a quick ratio of 3.11.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The company had revenue of $196.03 million during the quarter, compared to analyst estimates of $195.17 million. During the same quarter in the prior year, the business earned $0.08 earnings per share. The business’s revenue for the quarter was up .4% on a year-over-year basis. GoodRx has set its FY 2025 guidance at EPS. On average, research analysts anticipate that GoodRx will post 0.13 EPS for the current fiscal year.

Insider Activity at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total value of $95,084.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 4.53% of the stock is owned by insiders.

Hedge Funds Weigh In On GoodRx

A number of institutional investors and hedge funds have recently bought and sold shares of GDRX. Citizens Financial Group Inc. RI bought a new stake in shares of GoodRx during the first quarter worth $44,000. Jump Financial LLC bought a new stake in GoodRx during the 1st quarter worth about $49,000. Cetera Investment Advisers acquired a new stake in GoodRx in the 2nd quarter valued at about $50,000. Walled Lake Planning & Wealth Management LLC acquired a new stake in GoodRx in the 2nd quarter valued at about $55,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of GoodRx by 202.3% in the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock worth $56,000 after acquiring an additional 7,580 shares during the last quarter. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.